Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Price
ACRVStock
$2.18+61.76%52W
Market Cap$93.42M
P/E—
PEG Ratio—
Div yield—
Beta1.94
ACRV Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)27.12%
Price vs S&P 500 (4W)39.81%
VGM Score78.79
ACRV Earnings Surprise History
Q2 25-0.55est. -0.58
Q3 25-0.47est. -0.58
Q4 25-0.49est. -0.46
Q1 26-0.49est. -0.52
Q2 26-0.43est. -0.50
ACRV Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.21
4.21
4.21
4.21
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ACRVAcrivon Therapeutics, Inc. Common Stock | — | — | B | $2.18 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncology medicines paired with a proprietary proteomics platform designed to identify patients most likely to respond to treatment. Its lead program, prexasertib (ACR-368), is in Phase 2 development. The preclinical pipeline targets DNA damage response and cell cycle regulation pathways.